• 1
    Beyer DC, Thomas T, Hilbe J, Swenson V. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2003; 2: 7784
  • 2
    Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 242834
  • 3
    Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 193842
  • 4
    Graefen M, Noldus J, Pichlmeier U et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999; 36: 2130
  • 5
    Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 52834
  • 6
    Moul JW, Connelly RR, Lubeck DP et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166: 13227
  • 7
    Rasiah KK, Stricker PD, Haynes AM et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003; 98: 25605
  • 8
    ASTRO. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 103541
  • 9
    Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 18316
  • 10
    Gervasi LA, Mata J, Easley JD et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142: 3326
  • 11
    Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 4729
  • 12
    Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 6673
  • 13
    Diblasio CJ, Kattan MW. Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology 2003; 62 (Suppl. 1): 918
  • 14
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 55565
  • 15
    Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 5148
  • 16
    Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 16816
  • 17
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 84954
  • 18
    Anonymous. Occult axillary lymph-node micrometastases in breast cancer. Lancet 1990; 336: 4345
  • 19
    Shariat SF, Kattan MW, Erdamar S et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol 2003; 21: 122331
  • 20
    Deguchi T, Doi T, Ehara H et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993; 53: 53504
  • 21
    Ferrari AC, Stone NN, Eyler JN et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997; 89: 1498504
  • 22
    Okegawa T, Noda H, Kato M, Miyata A, Nutahara K, Higashihara E. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 2000; 44: 2108
  • 23
    Potter SR, Mangold LA, Shue MJ et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 2000; 89: 257786
  • 24
    Kurek R, Nunez G, Tselis N et al. Prognostic value of combined ‘triple’ reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004; 10: 580814
  • 25
    Martinez-Pineiro L, Rios E, Martinez-Gomariz M et al. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol 2003; 43: 34250
  • 26
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 4339
  • 27
    Allaf M, Partin AW, Walsh PC. Who is cured? How long after radical prostatectomy can PSA rise? In Annual Meeting of the AUA. Atlanta, USA: Elsevier, 2006
  • 28
    Edelstein RA, Zietman AL, De Las Morenas A et al. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996; 47: 3705
  • 29
    Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 2000; 163: 11838
  • 30
    Kuban D, Thames H, Levy L et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 2005; 61: 40914
  • 31
    Newling DW. Early versus late androgen deprivation therapy in metastatic disease. Urology 2001; 58 (Suppl. 1): 505
  • 32
    Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 28795
  • 33
    Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 2005; 19: 6518
  • 34
    Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol 2005; 48: 9005
  • 35
    Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004; 63: 6259
  • 36
    Chaussy C, Thuroff S, Rebillard X, Gelet A. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005; 2: 1918